Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

RAPT THERAPEUTICS, INC.

(RAPT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

RAPT Therapeutics : Wells Fargo Adjusts Price Target on RAPT Therapeutics to $65 From $30, Maintains Overweight Rating

06/15/2021 | 08:02am EDT


ę MT Newswires 2021
All news about RAPT THERAPEUTICS, INC.
07/07RAPT THERAPEUTICS : UBS Adjusts RAPT Therapeutics' Price Target to $55 From $23,..
MT
07/01RAPT THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
07/01Rapt Therapeutics, Inc. Announces Resignation of Peter Svennilson from Board ..
CI
06/23RAPT THERAPEUTICS : HC Wainwright Adjusts RAPT Therapeutics' Price Target to $56..
MT
06/21RAPT THERAPEUTICS : Piper Sandler Starts RAPT Therapeutics at Overweight With $6..
MT
06/18RAPT Therapeutics Announces Closing of Public Offering of Common Stock and Fu..
GL
06/16RAPT THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form ..
AQ
06/16RAPT THERAPEUTICS : Prices Common Stock Offering at $33 Per Share
MT
06/15RAPT Therapeutics Announces Pricing of Public Offering of Common Stock
GL
06/15AFTER HOURS WATCH LIST SCORECARD : Rapt, fusn, pdsb
MT
More news
Financials (USD)
Sales 2021 2,96 M - -
Net income 2021 -73,5 M - -
Net cash 2021 143 M - -
P/E ratio 2021 -11,1x
Yield 2021 -
Capitalization 1 021 M 1 021 M -
EV / Sales 2021 297x
EV / Sales 2022 841x
Nbr of Employees 67
Free-Float 97,5%
Chart RAPT THERAPEUTICS, INC.
Duration : Period :
RAPT Therapeutics, Inc. Technical Analysis Chart | RAPT | US75382E1091 | MarketScreener
Technical analysis trends RAPT THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 32,17 $
Average target price 63,33 $
Spread / Average Target 96,9%
EPS Revisions
Managers and Directors
Brian Russell Wong President, Chief Executive Officer & Director
Rodney K. B. Young CFO, Secretary & Principal Accounting Officer
William J. Rieflin Chairman
William Ho Chief Medical Officer
Dirk G. Brockstedt Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
RAPT THERAPEUTICS, INC.62.89%1 100
GILEAD SCIENCES, INC.18.47%85 134
WUXI APPTEC CO., LTD.37.17%71 226
REGENERON PHARMACEUTICALS21.37%57 013
BIONTECH SE245.88%55 555
VERTEX PHARMACEUTICALS-15.16%50 308